Carole Creuzenet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carole Creuzenet has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Najwa Zebian
Department of Microbiology & Immunology, Dental Sciences Building, Western University , London, ON, N6A 5C1
4 shared publicationsAlexandra Merkx-Jacques
Department of Microbiology and Immunology and
2 shared publicationsDinath Ratnayake
Microbiology and Immunology Western University London N6A5C1 Canada
2 shared publicationsMatthew McCallum
Department of Microbiology and Immunology, Infectious Diseases Research Group, University of Western Ontario, London, Ontario N6A 5C1, Canada
2 shared publications- Miguel A. Valvano
Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK
2 shared publications Sebastien Houle
INRS-Institut Armand Frappier, Laval, QC H7V 1B7, Canada
2 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 36 (5)
Comprehensive analysis of gp120 glycosylation to explore differences between transmitter/founder and chronic HIV-1 isolates
The extraordinary genetic diversity of HIV variants and their differences in glycosylation of surface protein gp120 have hindered developing a universal vaccine. Via lectin-mediated interactions, the gp120 glycans may trap viruses at the mucosal interface, enhance trans-infection of CD4+ T cells, or enhance HIV uptake for antigen presentation while limiting such presentation by inhibiting gp120 proteolysis. Also, variations in numbers and location of glycosylation sites may allow escape from emerging neutralizing antibodies. Thus, specific gp120 glycans may be critical for transmission and immune control. As most transmission events arise from a single transmitted founder virus (T/F), we surmise that a unique glycosylation signature in T/F viruses supports optimal transmission and could be targeted for vaccination. By combining mass spectrometry, computational analyses, structural modeling and lectin microarrays, this study provides a comprehensive, quantitative and site-specific analysis of gp120 N-glycosylation and its functional impact. The 24 and 27 N-linked glycosylation sites of gp120 from a T/F and a chronic HIV-1 isolate were interrogated for 55 glycoforms representing glycosylation steps across the endoplasmic reticulum and the Golgi. We showed that gp120 is more glycosylated in T/F virions than in chronic virions, both having unique glycosylation hot spots that influence lectin binding. These site-specific glycosylation differences may correlate with differential transmission fitness of the isolates. This proof-of-principle study will enable large-scale comparisons of complex N-glycosylation patterns of T/F and chronic viruses to fully test if unique glycan signatures influence HIV transmissibility and can be exploited for vaccine development.
- 24 March 2026
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 36 (5)
Open AccessComprehensive analysis of gp120 glycosylation to explore differences between transmitter/founder and chronic HIV-1 isolates
The extraordinary genetic diversity of HIV variants and their differences in glycosylation of surface protein gp120 have hindered developing a universal vaccine. Via lectin-mediated interactions, the gp120 glycans may trap viruses at the mucosal interface, enhance trans-infection of CD4+ T cells, or enhance HIV uptake for antigen presentation while limiting such presentation by inhibiting gp120 proteolysis. Also, variations in numbers and location of glycosylation sites may allow escape from emerging neutralizing antibodies. Thus, specific gp120 glycans may be critical for transmission and immune control. As most transmission events arise from a single transmitted founder virus (T/F), we surmise that a unique glycosylation signature in T/F viruses supports optimal transmission and could be targeted for vaccination. By combining mass spectrometry, computational analyses, structural modeling and lectin microarrays, this study provides a comprehensive, quantitative and site-specific analysis of gp120 N-glycosylation and its functional impact. The 24 and 27 N-linked glycosylation sites of gp120 from a T/F and a chronic HIV-1 isolate were interrogated for 55 glycoforms representing glycosylation steps across the endoplasmic reticulum and the Golgi. We showed that gp120 is more glycosylated in T/F virions than in chronic virions, both having unique glycosylation hot spots that influence lectin binding. These site-specific glycosylation differences may correlate with differential transmission fitness of the isolates. This proof-of-principle study will enable large-scale comparisons of complex N-glycosylation patterns of T/F and chronic viruses to fully test if unique glycan signatures influence HIV transmissibility and can be exploited for vaccine development.
- 12 June 2025
- Published by Springer Nature
- Vol. 2942, 63-79
Assays for Anti-Helicobacter pylori Effects of Lactic Acid Bacteria Secretions
Helicobacter pylori (HP) is a chronic bacterial pathogen that can cause gastric ulcers and cancers. The treatment for HP infections relies on a combination of antibiotics and proton pump inhibitors. Due to rising antibiotic resistance, curtailing HP-induced diseases requires identifying new anti-HP molecules that can reduce HP viability or impair its virulence, including its ability to cause inflammation. Oral intake of lactic acid bacteria (LAB) was shown to enhance the treatment of HP infection, and we demonstrated that LAB secretions can affect HP’s growth and virulence factor production. This article describes a panel of in vitro assays that can be used to screen the anti-HP properties of multiple LAB secretions for the identification of novel anti-HP agents. The assays pertain to effects on viability, motility, urease production, and ability to elicit inflammation in gastric cells.
- 12 June 2025
- Published by Springer Nature
- Vol. 2942, 63-79
Assays for Anti-Helicobacter pylori Effects of Lactic Acid Bacteria Secretions
Helicobacter pylori (HP) is a chronic bacterial pathogen that can cause gastric ulcers and cancers. The treatment for HP infections relies on a combination of antibiotics and proton pump inhibitors. Due to rising antibiotic resistance, curtailing HP-induced diseases requires identifying new anti-HP molecules that can reduce HP viability or impair its virulence, including its ability to cause inflammation. Oral intake of lactic acid bacteria (LAB) was shown to enhance the treatment of HP infection, and we demonstrated that LAB secretions can affect HP’s growth and virulence factor production. This article describes a panel of in vitro assays that can be used to screen the anti-HP properties of multiple LAB secretions for the identification of novel anti-HP agents. The assays pertain to effects on viability, motility, urease production, and ability to elicit inflammation in gastric cells.
- Open Access
- 20 February 2024
- Published by Wiley in Microbiologyopen
- Vol. 13 (1) , e1400
Effect of the polysaccharide capsule and its heptose on the resistance of Campylobacter jejuni to innate immune defenses
Campylobacter jejuni is a commensal in many animals but causes diarrhea in humans. Its polysaccharide capsule contributes to host colonization and virulence in a strain‐ and model‐specific manner. We investigated if the capsule and its heptose are important for interactions of strain NCTC 11168 with various hosts and their innate immune defenses. We determined that they support bacterial survival in Drosophila melanogaster and enhance virulence in Galleria mellonella. We showed that the capsule had limited antiphagocytic activity in human and chicken macrophages, decreased adherence to chicken macrophages, and decreased intracellular survival in both macrophages. In contrast, the heptose increased uptake by chicken macrophages and supported adherence to human macrophages and survival within them. While the capsule triggered nitric oxide production in chicken macrophages, the heptose mitigated this and protected against nitrosative assault. Finally, the C. jejuni strain NCTC 11168 elicited strong cytokine production in both macrophages but quenched ROS production independently from capsule and heptose, and while the capsule and heptose did not protect against oxidative assault, they favored growth in biofilms under oxidative stress. This study shows that the wild‐type capsule with its heptose is optimized to resist innate defenses in strain NCTC 11168 often via antagonistic effects of the capsule and its heptose.
- 20 February 2024
- Published by Wiley in Microbiologyopen
- Vol. 13 (1) , e1400
Open AccessEffect of the polysaccharide capsule and its heptose on the resistance of Campylobacter jejuni to innate immune defenses
Campylobacter jejuni is a commensal in many animals but causes diarrhea in humans. Its polysaccharide capsule contributes to host colonization and virulence in a strain‐ and model‐specific manner. We investigated if the capsule and its heptose are important for interactions of strain NCTC 11168 with various hosts and their innate immune defenses. We determined that they support bacterial survival in Drosophila melanogaster and enhance virulence in Galleria mellonella. We showed that the capsule had limited antiphagocytic activity in human and chicken macrophages, decreased adherence to chicken macrophages, and decreased intracellular survival in both macrophages. In contrast, the heptose increased uptake by chicken macrophages and supported adherence to human macrophages and survival within them. While the capsule triggered nitric oxide production in chicken macrophages, the heptose mitigated this and protected against nitrosative assault. Finally, the C. jejuni strain NCTC 11168 elicited strong cytokine production in both macrophages but quenched ROS production independently from capsule and heptose, and while the capsule and heptose did not protect against oxidative assault, they favored growth in biofilms under oxidative stress. This study shows that the wild‐type capsule with its heptose is optimized to resist innate defenses in strain NCTC 11168 often via antagonistic effects of the capsule and its heptose.
- Open Access
- 26 May 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11) , 5650
In Vitro Framework to Assess the Anti-Helicobacter pylori Potential of Lactic Acid Bacteria Secretions as Alternatives to Antibiotics
Helicobacter pylori is a prevalent bacterium that can cause gastric ulcers and cancers. Lactic acid bacteria (LAB) ameliorate treatment outcomes against H. pylori, suggesting that they could be a source of bioactive molecules usable as alternatives to current antibiotics for which resistance is mounting. We developed an in vitro framework to compare the anti-H. pylori properties of 25 LAB and their secretions against H. pylori. All studies were done at acidic and neutralized pH, with or without urea to mimic various gastric compartments. Eighteen LAB strains secreted molecules that curtailed the growth of H. pylori and the activity was urea-resistant in five LAB. Several LAB supernatants also reduced the urease activity of H. pylori. Pre-treatment of H. pylori with acidic LAB supernatants abrogated its flagella-mediated motility and decreased its ability to elicit pro-inflammatory IL-8 cytokine from human gastric cells, without reverting the H. pylori-induced repression of other pro-inflammatory cytokines. This study identified the LAB that have the most anti-H. pylori effects, decreasing its viability, its production of virulence factors, its motility and/or its ability to elicit pro-inflammatory IL-8 from gastric cells. Once identified, these molecules can be used as alternatives or complements to current antibiotics to fight H. pylori infections.
- 26 May 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11) , 5650
Open AccessIn Vitro Framework to Assess the Anti-Helicobacter pylori Potential of Lactic Acid Bacteria Secretions as Alternatives to Antibiotics
Helicobacter pylori is a prevalent bacterium that can cause gastric ulcers and cancers. Lactic acid bacteria (LAB) ameliorate treatment outcomes against H. pylori, suggesting that they could be a source of bioactive molecules usable as alternatives to current antibiotics for which resistance is mounting. We developed an in vitro framework to compare the anti-H. pylori properties of 25 LAB and their secretions against H. pylori. All studies were done at acidic and neutralized pH, with or without urea to mimic various gastric compartments. Eighteen LAB strains secreted molecules that curtailed the growth of H. pylori and the activity was urea-resistant in five LAB. Several LAB supernatants also reduced the urease activity of H. pylori. Pre-treatment of H. pylori with acidic LAB supernatants abrogated its flagella-mediated motility and decreased its ability to elicit pro-inflammatory IL-8 cytokine from human gastric cells, without reverting the H. pylori-induced repression of other pro-inflammatory cytokines. This study identified the LAB that have the most anti-H. pylori effects, decreasing its viability, its production of virulence factors, its motility and/or its ability to elicit pro-inflammatory IL-8 from gastric cells. Once identified, these molecules can be used as alternatives or complements to current antibiotics to fight H. pylori infections.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100352
Structure–function studies of the C3/C5 epimerases and C4 reductases of the Campylobacter jejuni capsular heptose modification pathways
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100352
Open AccessStructure–function studies of the C3/C5 epimerases and C4 reductases of the Campylobacter jejuni capsular heptose modification pathways
- Open Access
- 1 September 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (36) , 13248-13268
A general protein O-glycosylation machinery conserved in Burkholderia species improves bacterial fitness and elicits glycan immunogenicity in humans
- 1 September 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (36) , 13248-13268
Open AccessA general protein O-glycosylation machinery conserved in Burkholderia species improves bacterial fitness and elicits glycan immunogenicity in humans
- 17 November 2015
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 26 (4) , 386-397
Comprehensive analysis of flagellin glycosylation inCampylobacter jejuniNCTC 11168 reveals incorporation of legionaminic acid and its importance for host colonization
Campylobacter jejuni is the leading cause of bacterial gastroenteritis. It relies on several virulence factors for host colonization, including glycosylated flagella. C. jejuni NCTC 11168 modifies its flagellins with pseudaminic acid derivatives. It is also presumed to modify these proteins with legionaminic acid, although no glycopeptide evidence was available at the onset of this study. The enzyme encoded by cj1319 can be used to make legionaminic acid in vitro, but the pathway for legionaminic acid synthesis partially inferred by knockout mutagenesis in Campylobacter coli VC167 excludes Cj1319. To address this contradiction, we examined the presence of legionaminic acid in flagellin glycopeptides of wild-type (WT) C. jejuni NCTC 11168 and of a cj1319 knockout mutant. We used high-energy collision-induced dissociation to obtain amino acid sequences while also visualizing signature sugar oxonium ions. Data analysis was performed with PEAKS software, and spectra were manually inspected for glycopeptide determination and verification. We showed that legionaminic acid is present on the flagellins of C. jejuni NCTC 11168 and that flagellin glycosylation is highly heterogeneous, with up to six different sugars singly present at a given site. We found that the cj1319 mutant produces more legionaminic acid than WT, thus excluding the requirement for Cj1319 for legionaminic acid synthesis. We also showed that this mutant has enhanced chicken colonization compared with WT, which may in part be attributed to the high content of legionaminic acid on its flagella.
- 17 November 2015
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 26 (4) , 386-397
Comprehensive analysis of flagellin glycosylation inCampylobacter jejuniNCTC 11168 reveals incorporation of legionaminic acid and its importance for host colonization
Campylobacter jejuni is the leading cause of bacterial gastroenteritis. It relies on several virulence factors for host colonization, including glycosylated flagella. C. jejuni NCTC 11168 modifies its flagellins with pseudaminic acid derivatives. It is also presumed to modify these proteins with legionaminic acid, although no glycopeptide evidence was available at the onset of this study. The enzyme encoded by cj1319 can be used to make legionaminic acid in vitro, but the pathway for legionaminic acid synthesis partially inferred by knockout mutagenesis in Campylobacter coli VC167 excludes Cj1319. To address this contradiction, we examined the presence of legionaminic acid in flagellin glycopeptides of wild-type (WT) C. jejuni NCTC 11168 and of a cj1319 knockout mutant. We used high-energy collision-induced dissociation to obtain amino acid sequences while also visualizing signature sugar oxonium ions. Data analysis was performed with PEAKS software, and spectra were manually inspected for glycopeptide determination and verification. We showed that legionaminic acid is present on the flagellins of C. jejuni NCTC 11168 and that flagellin glycosylation is highly heterogeneous, with up to six different sugars singly present at a given site. We found that the cj1319 mutant produces more legionaminic acid than WT, thus excluding the requirement for Cj1319 for legionaminic acid synthesis. We also showed that this mutant has enhanced chicken colonization compared with WT, which may in part be attributed to the high content of legionaminic acid on its flagella.
- 11 April 2015
- Published by Wiley in Molecular Microbiology
- Vol. 96 (6) , 1136-1158
Role of capsular modified heptose in the virulence of Campylobacter jejuni
The Campylobacter jejuni capsular polysaccharide is important for virulence and often contains a modified heptose. In strain ATCC 700819 (a.k.a. NCTC 11168), the modified heptose branches off from the capsular backbone and is directly exposed to the environment. We reported previously that the enzymes encoded by wcaG, mlghB and mlghC are involved in heptose modification. Here, we show that inactivation of any of these genes leads to production of capsule lacking modified heptose and alters the transcription of other capsule modification genes differentially. Inactivation of mlghB or mlghC, but not of wcaG, decreased susceptibility to bile salts and abrogated invasion of intestinal cells. All mutants showed increased sensitivity to serum killing, especially wcaG::cat, and had defects in colonization and persistence in chicken intestine, but did not show significant differences in adhesion, phagocytosis and intracellular survival in murine macrophages. Together, our findings suggest that the capsular heptose modification pathway contributes to bacterial resistance against gastrointestinal host defenses and supports bacterial persistence via its role in serum resistance and invasion of intestinal cells. Our data further suggest a dynamic regulation of expression of this pathway in the gastrointestinal tract.
- 11 April 2015
- Published by Wiley in Molecular Microbiology
- Vol. 96 (6) , 1136-1158
Role of capsular modified heptose in the virulence of Campylobacter jejuni
The Campylobacter jejuni capsular polysaccharide is important for virulence and often contains a modified heptose. In strain ATCC 700819 (a.k.a. NCTC 11168), the modified heptose branches off from the capsular backbone and is directly exposed to the environment. We reported previously that the enzymes encoded by wcaG, mlghB and mlghC are involved in heptose modification. Here, we show that inactivation of any of these genes leads to production of capsule lacking modified heptose and alters the transcription of other capsule modification genes differentially. Inactivation of mlghB or mlghC, but not of wcaG, decreased susceptibility to bile salts and abrogated invasion of intestinal cells. All mutants showed increased sensitivity to serum killing, especially wcaG::cat, and had defects in colonization and persistence in chicken intestine, but did not show significant differences in adhesion, phagocytosis and intracellular survival in murine macrophages. Together, our findings suggest that the capsular heptose modification pathway contributes to bacterial resistance against gastrointestinal host defenses and supports bacterial persistence via its role in serum resistance and invasion of intestinal cells. Our data further suggest a dynamic regulation of expression of this pathway in the gastrointestinal tract.
- 11 February 2015
- Published by Wiley in Molecular Microbiology
- Vol. 96 (1) , 110-133
Characterization of Helicobacter pylori HP0231 (DsbK): role in disulfide bond formation, redox homeostasis and production of Helicobacter cystein‐rich protein HcpE
Helicobacter pylori is a human gastric pathogen that colonizes ∼ 50% of the world's population. It can cause gastritis, gastric or duodenal ulcers and also gastric cancer. The numerous side effects of available treatments and the emergence of antibiotic resistant strains are severe concerns that justify further research into H. pylori's pathogenic mechanisms. H. pylori produces secreted proteins that may play a role in virulence, including the Helicobacter cysteine-rich protein HcpE (aka HP0235). We demonstrate herein that HcpE is secreted in the culture supernatant both as a soluble protein and in association with outer membrane vesicles. We show that the structure of HcpE comprises an organized array of disulfide bonds. We identify DsbK (aka HP0231) as a folding factor necessary for HcpE production and secretion in H. pylori and show that recombinant DsbK can interact with and refold unprocessed, reduced HcpE in vitro. These experiments highlight the first biologically relevant substrate for DsbK. Furthermore, we show that DsbK has disulfide bond (Dsb) forming activity on reduced lysozyme and demonstrate a DsbA-type of activity for DsbK upon expression in E. coli, despite its similarity with DsbG. Finally, we show a role of DsbK in maintaining redox homeostasis in H. pylori.
- 11 February 2015
- Published by Wiley in Molecular Microbiology
- Vol. 96 (1) , 110-133
Characterization of Helicobacter pylori HP0231 (DsbK): role in disulfide bond formation, redox homeostasis and production of Helicobacter cystein‐rich protein HcpE
Helicobacter pylori is a human gastric pathogen that colonizes ∼ 50% of the world's population. It can cause gastritis, gastric or duodenal ulcers and also gastric cancer. The numerous side effects of available treatments and the emergence of antibiotic resistant strains are severe concerns that justify further research into H. pylori's pathogenic mechanisms. H. pylori produces secreted proteins that may play a role in virulence, including the Helicobacter cysteine-rich protein HcpE (aka HP0235). We demonstrate herein that HcpE is secreted in the culture supernatant both as a soluble protein and in association with outer membrane vesicles. We show that the structure of HcpE comprises an organized array of disulfide bonds. We identify DsbK (aka HP0231) as a folding factor necessary for HcpE production and secretion in H. pylori and show that recombinant DsbK can interact with and refold unprocessed, reduced HcpE in vitro. These experiments highlight the first biologically relevant substrate for DsbK. Furthermore, we show that DsbK has disulfide bond (Dsb) forming activity on reduced lysozyme and demonstrate a DsbA-type of activity for DsbK upon expression in E. coli, despite its similarity with DsbG. Finally, we show a role of DsbK in maintaining redox homeostasis in H. pylori.
- Open Access
- 1 July 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (27) , 19569-19580
Comparison of Predicted Epimerases and Reductases of the Campylobacter jejuni d-altro- and l-gluco-Heptose Synthesis Pathways
- 1 July 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (27) , 19569-19580
Open AccessComparison of Predicted Epimerases and Reductases of the Campylobacter jejuni d-altro- and l-gluco-Heptose Synthesis Pathways